• All
  • Company Report
  • Industry Report

Abbott Laboratories (ABT) – Rapid antigen test BinaxNOW for Covid 19 will boost revenue for next year

Abbott Laboratories achieved a number of product approvals which include the approval of MitraClip G4, the latest generation of market leading system to repair a leaky mitral heart valve. Highlights  Valuation – Enterprise Value – CrispIdea Forecast – Economic Value Added Analysis – DCF Analysis – P/E Analysis – Peer Valuation – CrispIdea Forecast Relative […]

Becton, Dickinson and Company (BDX) – COVID 19 Testing sales created positive impact on company performance

BDX’s expanding innovation pipeline is focused on healthcare’s shifting trends leveraging BD’s core strengths. The company is applying smart devices, robotics & analytics/AI to improve care processes and lower costs. Highlights  Valuation – Enterprise Value – CrispIdea Forecast – Economic Value Added Analysis – P/E Analysis – Peer Valuation – CrispIdea Forecast Relative to Consensus […]

Chemed Corporation (CHE – Q3FY20) – Quarter performance was led by growth in Roto- Rooter and VITAS.

Chemed Corporation, operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider. Executive Summary Financial Statements – Income Statement and Forecast – Balance Sheet – Cash Flow – Company Overview – Q3FY20 Results – Overview – Segment […]

Medtronic plc (MDT -Q2-FY21) – Recovery in business led to improvement in quarter performance.

MDT has increased their focus on allocating capital to their best opportunities, and they are supplementing this with an increased cadence of tuck in acquisitions. The company announced seven acquisitions in 2020 with total value of more than $1.6bn. Executive Summary  Financial Statements – Income Statement and Forecast – Balance Sheet – Cash Flow – […]

Becton, Dickinson and Co. (BDX – Q4FY20 & FY20) – Quarter performance positively affected by COVID-19 testing revenue.

BD Life Sciences segment, revenues for the quarter of $1.488bn increased 31.2% over the prior-year period. The segment’s results were driven by strong sales related to COVID-19 diagnostic testing solutions in the Diagnostic Systems unit on the BD VeritorTM and BD MaxTM platforms. Executive Summary Financial Statements – Income Statement and Forecast – Balance Sheet […]

AbbVie Inc (ABBV – Q3FY20) – Rinvoq and Skyrizi performance above expectation.

The combination with Allergan, have created a stronger, more diverse company with robust cash flows, and multiple new growth vehicles for the long term.  The company now have the leading franchise which is demonstrating a strong V-shape recovery, as well as a highly attractive neuroscience portfolio that delivered double-digit growth on a comparable operational basis […]

Boston Scientific Corporation (BSX – Q3FY20) – Acquisition of BTG plc contributed towards revenue growth.

BSX initiated the U.S. launch of the SpaceOAR Vue™ Hydrogel, a next-generation hydrogel spacer that is designed to reduce the side effects of prostate radiation therapy, while providing clinicians with the added ability to view the spacer using computerized tomography (CT) scans instead of magnetic resonance imaging (MRI). Executive Summary Financial Statements – Income Statement […]

Danaher Corp. (DHR – Q3FY20) – Quarter performance was positively affected by Cytiva acquisition.

Cytiva and Pall Biotech comprised most of the bioprocessing exposure; and collectively, these businesses increased orders by more than 60% in the quarter, driven by comprehensive offering across the bioprocessing workflow. Non-COVID-related bioprocessing activity remained healthy and in line with what the company saw over the last several quarters. Executive Summary Financial Statements – Income […]

Biogen Inc (BIIB – Q3FY20) – TECFIDERA sales decline is expected, impact the revenue growth.

TECFIDERA situation in the U.S. is clearly a near-term challenge for the company. During Q3FY20, the company began to experience the impact of generic entrants with more than 10 TECFIDERA generics approved and at least six now in the market, and discounted prices of ~90%. Executive Summary Financial Statements – Income Statement and Forecast – […]

Abbott Laboratories (ABT- Q3FY20) – Medical Devices and Diagnostics contributed towards revenue growth.

Abbott revenues increased by 9.6% to $8.85bn in Q3FY20. The increase was driven by an increase in the Diagnostics segment as a result of demand for Abbott’s portfolio of COVID 19 diagnostics tests on its lab based immunoassay and molecular diagnostics systems and point of care rapid testing platforms. Sales growth in Medical Devices and […]

Thermo Fisher Scientific’s Inc (TMO – Q3FY20) – Exceptional performance in the quarter due to growth in Life Sciences Solutions segment.

The company launched innovative Thermo Scientific products across businesses, highlighted by two Selectris imaging filters for cryo-electron microscopes that accelerate research in structural analysis of proteins, and the POROS Oligo (dT)25 Affinity Resin to advance mRNA-based therapies and vaccines. Executive Summary Financial Statements – Income Statement and Forecast – Balance Sheet – Cash Flow – […]

Medtronic plc (MDT-Q1FY21) – Product approvals and launches expected to lead the growth of the company.

Medtronic plc | is experiencing the benefit of new product launches as pipeline kicks in across the company. They had over 130 regulatory approvals this calendar year in the US, Europe, Japan, and China. Procedure volumes began to recover this quarter in multiple markets around the world, and drove market share gains in a number […]

Becton, Dickinson and Co. (BDX – Q3FY20) – Quarter performance affected by COVID-19 pandemic.

Becton, Dickinson and Co launched four new products in the quarter and remain on track to deliver robust innovation pipeline for the year. It launched an upgrade to the BD FACS Melody to expand from 2-way sorting to 4-way sorting, enabling customers to capture more cell types. Executive Summary Financial Statements – Income Statement and […]

Boston Scientific Corporation (BSX – Q2FY20) – Positive impact of Vertiflex acquisition on revenue.

Boston Scientific Corporation| will be launching LUX-Dx implantable cardiac monitor, which will offer a seamless patient interface and back-end monitoring. It will have the ability to be programmed remotely and have event detection settings adjusted without an in person visit. Executive Summary Financial Statements – Income Statement and Forecast – Balance Sheet – Cash Flow […]

AbbVie Inc (ABBV – Q2FY20) – Allergan acquisition contributed towards revenue growth.

The acquisition of Allergan has helped in creating a stronger and more diverse AbbVie. The transaction significantly expands and diversifies AbbVie’s revenue base through leadership positions in immunology and hematological oncology with additional growth franchises in aesthetics and neuroscience. The company experienced growth opportunities in neuroscience with Botox Therapeutics, Vraylar and Ubrelvy. Executive Summary Financial […]

Danaher Corp. (DHR – Q2FY20) – Cytiva acquisition to boost growth in FY21.

DHR revenues increased by 19.19% to $5.3bn in Q2FY20 and the acquisition of Cytiva contributed 21.5% to the increase in revenues. The company has increased the production capacity of diagnostic testing for COVID-19, since the test was launched, shipping more than 6mn test cartridge. Executive Summary Financial Statements – Income Statement and Forecast – Balance […]

Thermo Fisher Scientific’s Inc (TMO – Q2FY20) – Quarter performance positively affected by increase in demand.

Life Sciences Solutions Segment revenue increased by 52.16% to $2.6bn in Q2FY20 due to increased sales of genetic sciences products, driven primarily by tests for diagnosis of COVID-19. Sales grew, to a lesser extent, due to higher demand for biosciences and bio-production products. Executive Summary Financial Statements – Income Statement and Forecast – Balance Sheet […]

Biogen Inc (BIIB – Q2FY20) – Look forward to grow from aducanumab in Alzheimer’s disease.

Biogen Inc. and Denali Therapeutics Inc. announced that they have signed a binding agreement to codevelop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative […]

Abbott Laboratories (ABT Q2FY20) – FreeStyle Libre and COVID 19 test kits were the performance drivers.

Abbott announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of the company’s Patient Controller app on compatible personal Apple smartphone devices. At Abbott, this approval allows patients living with neurological conditions, including chronic pain or movement disorders, the ability to manage therapy directly from their personal smartphone. […]

Lam Research Corporation (LRCX – Q4FY20 and FY20) – Higher demand for NAND to drive WFE spending in 2021.

Lam Research and VELO3D, have entered into a partnership in a joint development agreement for novel materials and designs in metal additive manufacturing or 3D printing applications for the semiconductor industry. Over the next five years, Lam plans to significantly increase the volume of parts produced by AM. VELO3D will develop new metal alloys on […]

Medtronic plc (MDT Q4FY20 & FY20) – MDT’s performance was affected due to COVID 19 pandemic.

Medtronic plc, the global leader in medical technology, introduced the MiniMed™ Mio™ Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed™ portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps1. […]

Becton, Dickinson and Co. (BDX – Q2FY20) – Strong growth across business segments led to progress in Q2FY20.

Becton, Dickinson and Company completed the acquisition of Straub Medical, which will further expands the company’s portfolio with a proven device with that’s approved with dual indications for arterial atherectomy and thrombectomy in the U.S. It has solid existing sales in Europe and China. The company is leveraging their strong existing channel and expertise in […]

Danaher Corp. (DHR – Q1FY20) – Cytiva acquisition to boost growth in FY21.

Danaher Corporation announced it completed the sale of its label-free biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards, single use tangential flow filtration systems, and stainless steel hollow fiber tangential flow filtration systems businesses to Sartorius AG for approximately $825 million. The combined revenue of the businesses, which were part of Danaher’s […]

Biogen Inc (BIIB – Q1FY20) – Biogen look forward to grow from aducanumab in Alzheimer’s disease.

Biogen has opened BLA and has started to submit modules, expects to complete the U.S. filing for (Alzheimer’s drug) aducanumab in Q3FY20. It also initiated re-dosing study for aducanumab and higher dose study for SPINRAZA. The company entered collaboration with Sangamo Therapeutics for gene regulation therapies for neurological disease. Executive Summary Financial Statements – Income […]

Boston Scientific Corporation (BSX – Q1FY20) – Lower performance expected in coming quarters due to COVID-19.

Boston Scientific announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for patients with nonvalvular atrial fibrillation (NVAF). Presented as a late-breaking clinical trial at HRS 2020 SCIENCE, the study evaluated performance of the WATCHMAN FLX device as […]

Abbott Laboratories (ABT – Q1FY20) – Abbott’s near-term performance impacted by COVID-19.

Abbott recently launched three diagnostics tests for COVID 19, including molecular tests on its ID NOW™ rapid point of care platform and m 2000 RealTime lab based platform, and a serology blood test for the detection of the antibody, IgG, on its lab based immunoassay platforms. Organic sales growth in the quarter was led by strong […]

Global Market Performance YTD – 2019 – A dramatic performances by the stock markets

The U.S. economy grew by 1.9% in Q3FY19. There was a dip in net exports, private, fixed investments and inventories which weighed on the growth, but the consumer spending stabilized the American economy. The consumer confidence plummeted in August, post the fresh escalations to the U.S.- China trade war. There was a contraction in the […]

IMPACT INVESTING INDUSTRY – 2019 – A new wave of Social Change growing radically!

Impact investing is an exciting and rapidly growing industry powered by investors who are determined to generate social and environmental impact as well as financial returns. This is taking place all over the world, and across all asset classes. Table of Contents Executive Summary Overview Industry Analysis Result Based Financing Green Bonds Trends in 2019 […]

Medtronic plc – Double-digit growth in emerging market led to growth in FY19

Medtronic’s revenues increased by 2% to $30.56bn for FY19, which was below our guidance of $31.15bn for FY19. Revenues in Q4FY19 increased by $2mn to $8.14bn which adjusts for a $289mn negative impact from foreign currency No. of Pages – 44 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash Flow –Q4FY19 […]

AbbVie Inc (ABBV) – AbbVie showing progress in its pipeline by approval of SKYRIZI

AbbVie’s revenues declined by 1.3% to $7.83bn in Q1FY19 and increased by 0.4% operationally. The revenues declined due to a decrease in HUMIRA international revenues due to the biosimilar competition. However, HUMIRA revenues from the U.S. increased by 7.1% to $3.2bn in Q1FY19 and will not face biosimilar competition in the U.S. until FY23. Number […]

Thermo Fisher Scientific (TMO) – Acquisition of Brammer Bio will boost growth for TMO

TMO completed the acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for ~$1.7bn in cash. Brammer will become part of TMO’s Pharma Services business within its Laboratory Products and Services Segment. This acquisition will boost growth for the company and therefore, we expect 4% growth in revenues in […]

Danaher Corp. (DHR) – GE Biopharma acquisition will lead to the growth in future

DHR sales grew by 4% to $4.9bn in Q1FY19 with 5.5% core revenue growth. The acquisitions increased revenues by 2.5%, while the impact of foreign currency translation decreased revenues by 4% during the quarter. Number of Pages – 39 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash Flow –Q1FY19 Results – […]

Biogen Inc (BIIB) – Strong operational performance in MS, SMA and Biosimilar Franchises

Biogen delivered strong financial results during the quarter due to the strong operational performance of the MS, SMA, and biosimilars franchises. Total revenues increased by 11% to $3.5bn and adjusted EPS increased by 15% to $6.98 for Q1FY19. Number of Pages – 47 Contents Executive Summary Financial Statements –Income Statement and Forecast –Balance Sheet –Cash […]

Abbott Laboratories (ABT) – Double-digit growth in growth drivers – FreeStyle Libre, MitraClip and Alinity

Abbott delivered strong Q1FY19 performance with 2% growth in revenues on reported basis and 7.1% growth in revenues on an organic basis. The growth was due to double-digit growth in FreeStyle Libre, MitraClip and Alinity. The adjusted EPS grew by 6.8% to $0.63 in Q1FY19 Number of pages – 41 Content: Executive Summary………………………………………………………..1 Financial Statements […]